Major Late-Breaking Trials from EuroPCR 2026

Session comprising selected EuroPCR 2026 late-breaking trials submissions

Anchorperson: B. Prendergast

Spokesperson: N. Gonzalo

Summary

This session presents major late-breaking trials from EuroPCR 2026, reviewing contemporary evidence on coronary revascularization in TAVI patients, long-term outcomes of PCI versus CABG for left main disease, and comparative effectiveness of LAA closure versus NOAC in atrial fibrillation across age groups, with clinical practice implications.

Presentations available when logged in:

Coronary revascularisation in patients undergoing TAVI: an IPD meta-analysis of four randomised trials
Review and impact on clinical practice
Long-term mortality following PCI with DES vs. CABG for left main disease
Review and impact on clinical practice
Outcomes of LAA closure vs. NOAC in patients with atrial fibrillation across different age groups
Review and impact on clinical practice

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

Major Late-Breaking Trials from EuroPCR 2026

Session comprising selected EuroPCR 2026 late-breaking trials submissions

Log in or create account for free